Palupiprant

N/A

Report date: 2024/05/23 17:49:15
NME

Base Information

Drug NamePalupiprant
Drug Alias NameER-886046-00AN-0025E-7046AN0025
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProstanoid EP4 receptor antagonists
TargetsProstanoid EP4 receptor
Therapy Area/IndicationsUterine Cervical NeoplasmsCarcinoma, Non-Small-Cell LungLung Neoplasms +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPolandUnited Kingdom +[5] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesEisai Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesAdlai Nortye LtdHangzhou Adlai Nortye Biopharma Co Ltd
Inactive CompaniesRutgers UniversityEisai Inc
Active IndicationsUterine Cervical NeoplasmsCarcinoma, Non-Small-Cell LungRectal Neoplasms +[7] 
Inactive IndicationsLung NeoplasmsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A